L2.9 Kilder
Legemidler i behandlingen av kreftsykdommer
Adams VR, Leggas M (2007): Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 29, 1338-1353.
Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WP (2000): Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 6, 548-554.
Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F (2007): Erlotinib in cancer treatment. Ann Oncol. 18, vi35-vi41.
Bennouna J, Delord JP, Campone M, Nguyen L (2008): Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 14, 1625-1632.
Buesa JM, Urrechaga E (1991): Clinical pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol. 28, 475-479.
Buie LW, Epstein SS, Lindley CM (2007): Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 29, 1887-1899.
Carter NJ, Keam SJ (2007): Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67, 2257-2276.
Chang TK, Yu L, Goldstein JA, Waxman DJ (1997): Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7, 211-221.
Chattopadhyay S, Moran RG, Goldman ID (2007): Pemetrexed: biomedical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 6, 404-417.
Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL (2007): Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects with hemodialysis. J Clin Pharmacol. 47, 1466-1475.
Cheson BD, Dutcher BS (2005): Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol. 3, 117-124
Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT (2004): Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther. 26, 1199-1214.
Curran MP, Croom KF, Goa KL (2004): Spotlight on imatinib mesylate in chronic myeloid leukemia. BioDrugs 18, 207-210.
Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. 2009. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Deininger MW (2008): Nilotinib. Clin Cancer Res. 14, 4027-4031.
Desoize B, Madoulet C (2002): Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 42, 317-325.
Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A (2008): Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther. 8, 865-874.
Fleming RA (1997): An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17,146S-154S.
Gebbia V, Puozzo C (2005): Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf. 4, 915-928.
Gillis JC, Goa KL (1995): Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukemia. Drugs 50, 897-923.
Gwilt PR,Tracewell WG (1998): Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 34, 347-358.
Hartmann JT, Lipp HP (2006): Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 29, 209-230.
Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002): Intensiv kjemoterapi ved Burkitts lymfom og aggressivt non-Hodgkins lymfom.Tidsskr Nor Legeforen. 122, 364-369.
Houle JM, Clervoix N, Bain S, Spénard J (2006): Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium. Clin Pharmacokinet- 45, 923-930.
Issa JPJ, Kantarjian HM, Kirkpatrick P (2005): Azacitidine. Nature Rev Drug Discovery 4, 275-276.
James CA, Mant TG, Rogers HJ (1987): Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol- 23, 561-568.
Jones RJ (2008): Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther- 6, 1311-1317.
Jurlina JL, Varcoe AR, Paxton JW (1985): Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother Pharmacol- 14, 21-25.
Kitamura T (2001): Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. Int J Urol. 8, 33-36.
Kumar S, Rajkumar SV (2006): Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42, 1612-1622.
Langer SW (2007): Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther. 7, 1081-1088.
Lobert S, Puozzo C (2008): Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 35 (Suppl 3), S28-S33.
Narta UK, Kanwar SS, Azmi W (2007): Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 61, 208-221.
Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R (2009): Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. Clin Ther. 31, 386-398.
Reck M (2009): Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 9, 401-412.
Reigner B, Blesch K, Weidekamm E (2001): Clinical pharmaokinetics of capecitabine. Clin Pharmacokinet. 40, 85-104.
Ricciardi S, Tomao A, de Marinis F (2009): Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10, 28-35.
Sanford M, Plosker GL (2008): Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. Drugs 68, 1319-1340.
Sanford M, Lyseng-Williamson KA (2008): Nelarabine. Drugs 68, 439-447.
Schteingart DE (2007): Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med. 356, 2415-2418.
Schwartz R, Davidson T (2004): Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 18, 14-21.
Scripture CD, Sparreboom A, Figg WD (2005): Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 6, 780-789.
Siddiqui MAA, Scott LJ (2005): Azacitidine in myelodysplastic syndromes. Drugs 65, 1781-1789.
Spratlin J, Sawyer MB (2007): Pharmacogenetics of paclitaxel metabolim. Crit Rev Oncol Hematol. 61, 222-229.
Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007): Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patinets with advanced refractory solid tumors. Oncologist 12, 426-437.
Triesscheijn M, Ruevekamp M, Out R, Van Berkel TJ, Schellens J, Baas P, Stewart FA (2007): The pharmacokinetic behavior of the photosensitizer meso-tetra-heydroxyphenylchlorin in mice and men. Cancer Chemother Pharmacol. 60, 113-122.
van Schaik RH (2008): CYP450 pharmacogenetics for peronalizing cancer therapy. Drug Resist Updat. 11, 77-98.
Verweij J, Pinedo HM (1990): Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1, 5-13.
Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D (2005): Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess. 9, 1-142.
Yun-San Yip A, Yen-Yen Ong E, Chow LW (2008): Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs 17, 583-591.
Preparatomtaler: www.legemiddelverket.no , www.ema.europa.eu , www.medicines.org.uk , www.medsafe.govt.nz , www.axcan.com
Abemaciklib
Afatinib
D'Arcangelo M, Hirsch FR (2014): Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics. 8, 183-192.
Keating GM (2014): Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs. 74, 207-221.
Lee CC, Shiao HY, Wang WC, Hsieh HP (2014): Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs. Jun 12, 1-16. [Epub ahead of print].
Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J (2013): Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 72, 1213-1222.
Preparatomtale Giotrif (www.legemiddelverket.no).
Aflibercept
Dietvorst MH, Eskens FA. Current and novel treatment options for metastatic colorectal cancer: Emphasis on aflibercept. Biol Ther. 2013; 3: 25-33.
Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012; 38: 484-493.
Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7:167-180.
Preparatomtale Zaltrap (www.legemiddelverket.no)
Aksitinib
Ho TH, Jonasch E (2011): Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol 7, 1247-1253.
Patson B, Cohen RB, Olszanski AJ (2012): Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol 8, 259-270.
Posadas EM, Figlin RA (2012): Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) 26, 290-301.
Preparatomtale Inlyta (www.legemiddelverket.no)
Alektinib
Preparatomtale Alecensa (SPC)
Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016; 34(7): 661-8.
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016; 17(2): 234-42.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017. doi: 10.1016/S0140-6736(17)30565-2.
Atezolizumab
Aksikabtagenciloleucel
Azacitidin
Siddiqui MAA, Scott LJ (2005): Azacitidine in myelodysplastic syndromes. Drugs 65, 1781-1789.
Issa JPJ, Kantarjian HM, Kirkpatrick P (2005): Azacitidine. Nature Rev Drug Discovery 4, 275-276.
Preparatomtale Vidaza (www.legemiddelverket.no)
Bendamustin
Garnock-Jones KP (2010): Bendamustine. A review og its use in the management of indolent Non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 70, 1703-1718.
Seung AH (2010): Standard of care and novel treatments for chronic lymphocytic leukemia. Am J Health-Syst Pharm. 67, 1813-1824.
Tageja N, Nagi J (2010): Bendamustine: something old, something new. Cancer Chemoter Pharmacol 66, 413-423.
Binimetinib
Bosutinib
Abbas R, Hug BA, Leister C, Gaaloul ME, Chalom S, Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012; 69: 221-227.
Keller-v.Amsberg G, Brümmendorf TH. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2012; 12: 1121-7112.
Shen AQ, Wilson NM, Gleason SL, Khoury HJ. Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview. Ther Adv Hematol. 2014; 5: 13-17.
Rassi FE, Khoury HJ. Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia. Pharmgenomics Pers Med. 2013; 6: 57-62.
Preparatomtale Bosulif (www.legemiddelverket.no)
Brentuksimab vedotin
Chen X, Soma LA, Fromm JR. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther. 2013; 7: 45-56.
Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013; 19: 22-27.
Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs. 2013; 73: 371-381.
Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O'Connor OA.CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013; 53: 866-877.
Preparatomtale Adcetris (www.legemiddelverket.no)
Brigatinib
Cemiplimab
Cemiplimab SPC
Ceritinib
Kaczmar J, Mehra R: The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer. Ther Adv Respir Dis. 2015, 9: 236-241.
Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C: Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer. 2015, 16: 86-91.
Dabrafenib
Gibney GT, Zager JS (2013): Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 9, 893-899.
Kainthla R, Kim KB, Falchook GS (2013): Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomics Pers Med. 7, 21-29.
Mavropoulos JC, Wang TS (2014): Managing the skin toxicities from new melanoma drugs. Curr Treat Options Oncol. 15, 281-301.
Ouellet D, Gibiansky E, Leonowens C, O'Hagan A, Haney P, Switzky J, Goodman VL (2014): Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol. 54, 696-706.
Preparatomtale Tafinlar (www.legemiddelverket.no).
Dakomitinib
Daratumumab
Dasatinib
McFarland KL, Wetzstein GA (2009): Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitors. Cancer Control 16, 132-140
Steinberg M (2007): Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29: 2289-2308.
Preparatomtale Sprycel (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Deksrazoksan
Langer SW (2007): Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther 7:1081-1088.
Jones RJ (2008): Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther 6, 1311-1317.
Preparatomtale Savene (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Durvalumab
Beslutningsforum: https://nyemetoder.no/metoder/durvalumab-imfinzi
Enkorafenib
SPC Enkorafenib
Eribulin
Cortes J, Vidal M (2012). Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 133, 821-830.
Preston JN, Trivedi MV (2012): Eribulin: a novel cytotoxic chemotherapy agent. Ann Pharmacother 46, 802-811.
Scarpace SL (2012): Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer. Clin Ther 34, 1467-1473.
Preparatomtale Halaven (www.legemiddelverket.no)
Gefitinib
Reck M (2009) Exp Rev Anticancer Ther 9, 401-402.
Hartmann JT, Haap M, KOpp HG, Lipp HP (2009) Curr Drug Metab 10. 470-481.
Ricciardi, S, Tomao A, de Marinis F (2009) Clin Lung Cancer 10, 28-35.
Preparatomtale Iressa (www.ema.europa.eu).
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Gemtuzumab ozogamicin
Histamin
Yang LPH, Perry CM (2011): Histamine dihydrochloride in the management of acute myeloid leukaemia. Drugs 7, 102-122.
Martner A, Thorén FB, Aurelius J, Söderholm J, Brune M, Hellstrand K (2010): Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev Hematol 3, 381–391.
Preparatomtale Ceplene (www.legemiddelverket.no)
Ibrutinib
Burger JA et al.. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17; 373(25): 2425-37.
Byrd JC et al.. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 17; 371(3): 213-23
Idelalisib
Forcello N, Saraiya N. Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL. J Adv Pract Oncol. 2014, 5: 455-9.
Shah A, Mangaonkar A. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia. Ann Pharmacother. 2015, 49: 1162-70. Foreningen
Produktomtale Zydelig (www.legemiddelverket.no)
SLV. Begrensninger for bruk av Zydelig (idelalisib) etter resultater fra nye kliniske studier.
Inotuzumab
Ipilimumab
Graziani G, Tentori L, Navarra P (2012): Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65, 9-22.
Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F (2012): The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 48, 237-242.
Lens M, Testori A, Ferucci PF (2012): Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. Curr Top Med Chem 12, 61-66.
Trinh VA, Hwu WJ (2012): Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther 12, 773-782.
Preparatomtale Yervoy (www.legemiddelverket.no)
Kabazitaxel
Preparatomtale (www.legemiddelverket.no)
Michielsen DPJ, Braeckman JG, Denis L (2011): Cabazitaxel for the treatment of prostate cancer. Expert Opin. Pharmacother. 12, 977-982.
Pal SK, Twardowski P, Sartor O (2010): Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 5, 395-402.
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L,Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X (2011): Cabazitaxel: a novel microtubule inhibitor. Drugs 71, 1251-1258.
Karfilzomib
Andreu-Vieyra C, Berenson JR. Carfilzomib in multiple myeloma. Expert Opin Biol Ther. 2014 14:1685-99. Foreningen
Sugumar D, Keller J, Vij R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med. 2015,8:23-33
Produktbeskrivelse Kyprolis (www.legemiddelverket.no)
Klofarabin
Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JA, Weitman S (2006): Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5, 855-863.
Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S (2007): Clofarabine: past, present, and future. Leuk Lymphoma 48, 1922-1930.
Robak T, Korycka A, Lech-Maranda E, Robak P (2009): Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14, 1183-1226.
Larson ML, Venugopal P (2009): Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother 10, 1353-1357.
Preparatomtale Evoltra (www.legemiddelverket.no)
Kobimetinib
Garnock-Jones GP. Cobimetinib: First Global Approval. Drugs 2015, 75:1823–1830.
Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, Kloxin AM, Maverakis E. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther. 2015, 10:43-52.
Produktbeskrivelse Cotellic (www.legemiddelverket.no)
Krizotinib
Curran MP (2012): Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72, 99-107.
Forde PM, Rudin CM (2012): Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 13, 1195-1201.
Gandhi L, Jänne PA (2012): Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 18, 3737-3742.
Preparatomtale Xalkori (www.legemiddelverket.no)
Xalkori: EPAR – public assassment report (www.ema.europa.eu)
Lapatinib
Medina PJ, Goodin S (2008): Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30, 1426-1447.
Ulhoa-Cintra A, Greenberg L, Geyer CE (2008): The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep 10, 10-17.
Preparatomtale Atriance (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Lenalidomid
Kumar S, Rajkumar SV (2006): Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42, 1612-1622.
Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A (2008): Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8, 865-874.
Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL (2007): Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects with hemodialysis. J Clin Pharmacol 47, 1466-1475.
Preparatomtale Revlimid (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Lenvatinib
Scott LJ: Lenvatinib: first global approval. Drugs. 2015, 75: 553-560.
Lorlatinib
SPC.
Lu-DOTA-TATE
Strosberg J, El-Haddad G, Wolin E, Hendifar A, et. al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1).N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709 PMCID: PMC5895095 DOI: 10.1056/NEJMoa1607427 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607427
Mifamurtid
Frampton JE (2010): Mifamurtide. A review of its use in the treatment of osteosarcoma. Pediatr Drugs 12, 141-153.
Meyers PA (2009): Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9, 1035-1049
Nelarabin
Sanford M, Lyseng-Williamson KA (2008): Nelarabine, Drugs 68, 439-447.
Buie LW, Epstein SS, Lindley CM (2007): Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther 29, 1887-1899.
Curbo S, Karlsson A (2006): Nelarabine: a new purine analog in the treatment of hematologic malignancies. Rev Recent Clin Trials 1, 185-192.
Preparatomtale Atriance (www.legemiddelverket.no).
Nilotinib
Deininger MW (2008): Nilotinib. Clin Cancer Res 14, 4027-4031.
DeRemer DL, Ustun C, Natarajan K (2008) Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ter 30, 1956-1975.
Preparatomtale Tasigna (www.legemiddelverket.no).
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Nivolumab
Sunshine J, Taube, JM: PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015, 23:32-38.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW: Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286-93.
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clinical Therapeutics, 37(4), 764-782. doi:http://dx.doi.org/10.1016/j.clinthera.2015.02.018
Obinutuzumab
Marcus R, Davies A, Ando K. et. al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017; 377(14): 1331-1344. doi: 10.1056/NEJMoa1614598. PMID: 28976863
Ofatumumab
Preparatomtale (www.legemiddelverket.no)
O’Brien S, Österborg A (2010): Ofatumumab: A new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 10, 361-368.
Sanford M, McCormack PL (2010): Ofatumumab. Drugs 70, 1013-1019.
Reagan JL, Castillo JJ (2011): Ofatumumab for newly diagnosed and relapsed/ refractory chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 11, 151–160.
Olaparib
Preparatomtale Lynparza (http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf)
Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs 2015; 29: 143–150.
Chen Y, Zhang L, Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet. 2013; 288: 367–374.
Sehouli J, Braicu EI, Chekerov R. PARP inhibitors for recurrent ovarian carcinoma: current treatment options and future perspectives. Geburtshilfe Frauenheilkd. 2016; 76: 164-169.
Osimertinib
Preparatomtale Tagrisso (http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/004124/WC500202022.pdf)
Yver A. Osimertinib (AZD9291) - a science-driven, collaborative approach to rapid drug design and development. Ann Oncol. 2016 Mar 8. pii: mdw129.
Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016; 16: 383-390.
Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016; 77: 767-776.
Greig SL. Osimertinib: First Global Approval. Drugs. 2016; 76: 263-273.
Palbociklib
Preparatomtale (www.legemiddelverket.no)
Sherr CJ. A New Cell-Cycle Target in Cancer Inhibiting Cyclin D–Dependent Kinases 4 and 6. N Engl J Med. 2016; 375(20): 1920-1923.
Finn RS, Martin M, Hope S. Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20): 1925-1936.
Panitumumab
Preparatomtale (www.legemiddelverket.no)
Fakih M (2008): Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology (Williston Park) 22, 74-76.
Keating GM (2010): Panitumumab: A review of its use in metastatic colorectal cancer. Drugs 70, 1059-1078.
Peeters M, Balfour J, Arnold D (2008): Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther. 28, 269-281.
Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, Ruixo JJP (2010): Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet. 49, 729-740.
Pazopanib
Bukowski RM (2010): Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10, 635–645.
LaPlant KD, Louzon PD (2010): Pazopanib: An oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother 44, 1054-1060.
Pembrolizumab
Sunshine J, Taube, JM: PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015, 23:32-38.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW: Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1;21(19):4286-93.
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clinical Therapeutics, 37(4), 764-782. doi:http://dx.doi.org/10.1016/j.clinthera.2015.02.018
Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Oct 8. PMID: 27718847 DOI: 0.1056/NEJMoa1606774
Pertuzumab
Lamond NW, Younis T (2014): Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. Int J Womens Health. 6, 509-521.
Lynce F, Swain SM (2014): Pertuzumab for the treatment of breast cancer. Cancer Invest. Jun 12. [Epub ahead of print].
Maly JJ, Macrae ER (2014): Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival (2014): Breast Cancer (Auckl). 8, 81-88.
McCormack PL (2013): Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 73, 1491-1502.
Preparatomtale Perjeta (www.legemiddelverket.no).
Piksantron
Jamal-Hanjani M, Pettengell R (2011): Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opin Drug Metab Toxicol 7, 1441-1448
Mukherji D, Pettengell R (2010): Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opin Pharmacother 11, 1915-1923.
Papadatos-Pastos D, Pettengell R (2013): Pixantrone: merging safety with efficacy. Expert Rev Hematol 6, 25-33.
Preparatomtale Pixuvri (www.legemiddelverket.no)
Polatuzumabvedotin
Pomalidomid
Butler TW, Waddell JA, Solimando DA Jr. Drug monographs: pomalidomide and ponatinib. Hosp Pharm. 2013; 48: 636-641.
Elkinson S, McCormack PL. Pomalidomide: first global approval. Drugs. 2013; 73: 595-604.
Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013; 71: 489-501.
Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013; 122: 2305-2309.
EMA/306855/2013, 30 May 2013, Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation), Pomalidomide Celgene (http://www.ema.europa.eu)
Imnovid SPC (www.medicines.org.uk)
Radium-223
Brady D, Parker CC, O'Sullivan JM (2013): Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 19, 71-78.
Hafeez S1, Parker C (2013): Radium-223 for the treatment of prostate cancer. Expert Opin Investig Drugs. 22, 379-387.
Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A (2014): Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. Ther Clin Risk Manag. 10, 373-380.
Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H (2013): Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 19, 5822-5827.
Zustovich F, Fabiani F (2014): Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. Crit Rev Oncol Hematol. 91, 197-209.
Preparatomtale Xofigo (www.legemiddelverket.no)
Regorafenib
Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD (2014): Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 19, 669-680.
Lyseng-Williamson KA (2013): Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib. BioDrugs. 27, 525-531.
Strumberg D1, Schultheis B (2012): Regorafenib for cancer. Expert Opin Investig Drugs. 21, 879-889.
Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, Mitsunaga S, Hashizume K, Ito Y, Sasaki Y( 2014): Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 32, 104-112. (Erratum in Invest New Drugs. 2014, 32, 388.)
Preparatomtale Stivarga (www.legemiddelverket.no)
Ribosiklib
Ruxolitinib
Barosi G (2012): Emerging targeted therapies in myelofibrosis. Expert Rev Hematol 5, 313–324.
Naqvi K, Verstovsek S, Kantarjian H, Ravandi F (2011): A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs (2011) 20, 1159-1166.
Passamonti F, Maffioli M, Caramazza D (2012): New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol 19, 117–123.
Preparatomtale Jakavi (www.legemiddelverket.no)
Talidomid
von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A (2008): A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 81, 247-252.
Patel MP, Chanan-Khan AA (2009): The many lives of thalidomide. Leuk Lymphoma 50, 861-862.
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004): Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 43, 311-327.
Kumar S, Rajkumar SV (2006): Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42, 1612-1622.
Sleijfer S, Kruit WH, Stoter G (2004): Thalidomide in solid tumours: the resurrection of an old drug.Eur J Cancer 40, 2377-2382.
Preparatomtale Thalidomide Celgene/Pharmion (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Tegafur-gimeracil-oteracil
Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother. 2012 Sep;13(13):1943-59.
Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). Oncologist. 2011;16(10):1451-7
Preparatomtale Teysuno (www.legemiddelverket.no)
Temsirolimus
Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr Opin Oncol. 2013; 25 Suppl 2: S1-S12.
Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf. 2012; 11: 861-879.
Goodwin RA, Jamal R, Tu D, Walsh W, Dancey J, Oza AM, Elit L, Eisenhauer EA. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2013; 131: 315-320.
Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014; 89: 179-196.
Preparatomtale Torisel (www.legemiddelverket.no)
Tiotepa
Nieto Y, Vaughan WP (2004): Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33, 259-269.
O'Dwyer PJ, LaCreta F, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, DeVito J, Poplack D, DeLap RJ, Comis RJ (1991): Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res 51, 3171-3176.
Tisagenlekleucel
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
Trabektedin
Carter NJ, Keam SJ (2007): Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67, 2257-2276.
Preparatomtale Yondelis (www.legemiddelverket.no)
Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.
Trametinib
Lugowska I, Koseła-Paterczyk H, Kozak K, Rutkowski P: Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 2015, 25, 2251-2259.
Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13, 773-781.
Trastuzumab emtansin
Ballantyne A, Dhillon S (2013): Trastuzumab emtansine: first global approval. Drugs. 73, 755-765.
Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC, Roukos DH (2014): Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther. 7, 491-500.
Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin JY (2014): Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Jun 18. [Epub ahead of print] .
Sapra P, Betts A, Boni J (2013): Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacol. 6, 541-555.
Sawaki M (2014): Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press). 6, 37-41.
Preparatomtale Kadcyla (www.legemiddelverket.no).
Treosulfan
Trecondi SPC
Tivozanib
Tukatinib
Sirhan, Z., Thyagarajan, A. & Sahu, R.P. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Med Res 9, 39 (2022). https://doi.org/10.1186/s40779-022-00401-3.
Vandetanib
Frampton JE (2012): Vandetanib in medullary thyroid cancer. Drugs 72, 1423-1436.
Langmuir PB, Yver A (2012): Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 91, 71-80.
Zang J, Wu S Tang L, Xu X, Bai J, Ding C, Chang Y, Yue L, Kang E, He J (2012): Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: A systematic review and meta-analysis. PLoS ONE 7, e30353.
Preparatomtale Caprelsa (www.legemiddelverket.no)
Vemurafenib
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (2012): Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11, 873-86.
Heakal Y, Kester M, Savage S (2011): Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 45, 1399-1405.
Ravnan MC, Matalka MS (2012): Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Clin Ther 34, 1474-1486.
Preparatomtale Zelboraf (www.legemiddelverket.no)
Venetoklaks
Vinflunin
Bennouna J, Delord JP, Campone M, Nguyen L: Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008 14: 1625-1632.
Yun-San Yip A, Yuen-Yuen Ong E, Chow LW: Vinflunine: clinical perspectives of an emerging anticancer agent. Expert Opin Investig Drugs. 2008, 17:583-591.
Lobert S, Puozzo C: Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol. 2008, 35(Suppl 3): S28-33.
Preparatomtale Javlor (www.legemiddelverket.no)
Vismodegib
Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012; 34: 2039-2050.
Keating GM. Vismodegib: in locally advanced or metastatic basal cell carcinoma. Drugs. 2012; 72: 1535-1541.
Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011; 17: 5774-5782.
Poggi L, Kolesar JM. Vismodegib for the treatment of basal cell skin cancer. Am J Health Syst Pharm. 2013; 70: 1033-1038.
Preparatomtale Erivedge (www.legemiddelverket.no)